Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. IBM
3. PRIM
4. MU
5. DPZ
6. NAVN
7. DFTX
8. META
9. IMNN
10. ACN

Go back to Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis

Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

February 8, 2021 12:12 PM EST

Inrebic, a once-daily, oral therapy, is the first new treatment option approved in Europe for myelofibrosis in nearly a decade

Inrebic demonstrated clinically meaningful spleen and symptom response in myelofibrosis patients where treatment with ruxolitinib has failed, who are intolerant to ruxolitinib or who are JAK inhibitor naïve, based on results from JAKARTA and JAKARTA2 studies

PRINCETON, N.J.--(BUSINESS... More